DERM insider transaction filings
Journey Medical Corp — 34 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-02. Screen DERM transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-02 | 4 | Smith Justin Adam — Director | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2026-07-02 | 4 | Toledano Miranda Jayne — Director | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2026-07-02 | 4 | Herskowitz Neil — Director | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2026-06-29 | 4 | Toledano Miranda Jayne — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2026-06-26 | 4 | Smith Justin Adam — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2026-06-26 | 4 | ROSENWALD LINDSAY A MD — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2026-06-26 | 4 | Pearce Michael Cooper — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2026-06-26 | 4 | Herskowitz Neil — Director | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2026-04-24 | 4 | Alloush Ramsey — Chief Operating Officer | Grant/award (A): 46,863 @ $0 · Grant/award (A): 62,795 (derivative) @ $0 | EDGAR |
| 2026-04-24 | 4 | Benesch Joseph — CFO | Grant/award (A): 28,907 @ $0 · Grant/award (A): 41,860 (derivative) @ $0 | EDGAR |
| 2026-04-24 | 4 | Maraoui Claude — President & CEO, Director | Grant/award (A): 49,277 @ $0 · Grant/award (A): 82,915 (derivative) @ $0 | EDGAR |
| 2025-08-26 | 4 | Maraoui Claude — President & CEO, Director | Option exercise (M): 1,250,000 @ $0.07 · Tax withholding (F): 10,877 @ $7.47 · Option exercise (M): 1,250,000 (derivative) @ $0 | EDGAR |
| 2025-08-07 | 4 | ROSENWALD LINDSAY A MD — Director | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2025-08-07 | 4 | Smith Justin Adam — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-08-07 | 4 | Toledano Miranda Jayne — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-08-07 | 4 | Pearce Michael Cooper — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-08-07 | 4 | Herskowitz Neil — Director | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-07-07 | 4 | ROSENWALD LINDSAY A MD — Director | Grant/award (A): 7,173 @ $0 | EDGAR |
| 2025-07-07 | 4 | Smith Justin Adam — Director | Grant/award (A): 7,173 @ $0 | EDGAR |
| 2025-07-07 | 4 | Toledano Miranda Jayne — Director | Grant/award (A): 7,173 @ $0 | EDGAR |
| 2025-07-07 | 4 | Pearce Michael Cooper — Director | Grant/award (A): 7,173 @ $0 | EDGAR |
| 2025-07-07 | 4 | Herskowitz Neil — Director | Grant/award (A): 7,173 @ $0 | EDGAR |
| 2025-06-20 | 4 | Alloush Ramsey — Chief Operating Officer | Grant/award (A): 46,863 @ $0 · Grant/award (A): 62,795 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Benesch Joseph — CFO | Grant/award (A): 28,907 @ $0 · Grant/award (A): 41,860 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Maraoui Claude — President & CEO, Director | Grant/award (A): 49,277 @ $0 · Grant/award (A): 82,915 (derivative) @ $0 | EDGAR |
| 2025-05-05 | 4 | Maraoui Claude — President & CEO, Director | Sale (S): 4,834 @ $6.84 | EDGAR |
| 2025-05-05 | 4 | Benesch Joseph — CFO | Sale (S): 2,409 @ $6.84 | EDGAR |
| 2025-05-05 | 4 | Alloush Ramsey — COO | Sale (S): 2,857 @ $6.84 | EDGAR |
| 2025-04-16 | 4 | Maraoui Claude — President & CEO, Director | Grant/award (A): 175,000 @ $0 · Grant/award (A): 175,000 @ $0 | EDGAR |
| 2025-04-16 | 4 | Benesch Joseph — CFO | Grant/award (A): 80,000 @ $0 · Grant/award (A): 80,000 @ $0 | EDGAR |
| 2025-03-11 | 4 | Maraoui Claude — President & CEO, Director | Sale (S): 49,271 @ $5.01 | EDGAR |
| 2025-03-10 | 4 | Maraoui Claude — President & CEO, Director | Sale (S): 25,551 @ $5.04 · Sale (S): 14,905 @ $5.01 | EDGAR |
| 2025-03-05 | 4 | Maraoui Claude — President & CEO, Director | Sale (S): 23,508 @ $5.19 · Sale (S): 28,901 @ $5.04 · Sale (S): 18,147 @ $5.13 | EDGAR |
| 2025-02-24 | 4 | Benesch Joseph — CFO | Sale (S): 1,365 @ $5.19 | EDGAR |
Recent 8-K events — Journey Medical Corp
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-21 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-25 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | EDGAR |
| 2025-08-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-14 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=DERM returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →